INO Share Price Performance
US$1.05
-0.53 (-33.54%)
41.7% undervalued intrinsic discount
US$1.80
Fair Value
Price US$1.05
AnalystLowTarget US$1.80
AnalystHighTarget US$13.00
AnalystConsensusTarget US$7.63
Fair ValueUS$1.80
Share Pricen/a
Inovio Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 35 Fair Values set on narratives written by author
INO Community Narratives
AN
Fair Value US$1.8 41.7% undervalued intrinsic discount
Regulatory And Commercial Risks Around DNA Medicines Will Eventually Support A Healthier Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$13 91.9% undervalued intrinsic discount
RRP Treatment Breakthrough Will Transform DNA Medicines Platform Into A Durable Revenue Franchise
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$7.63 86.2% undervalued intrinsic discount
DNA Medicines And Rare Disease Focus Will Transform Into A Future Commercial Revenue Story
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Regulatory And Commercial Risks Around DNA Medicines Will Eventually Support A Healthier Outlook
Catalysts About Inovio Pharmaceuticals Inovio Pharmaceuticals focuses on developing DNA medicines, including INO-3107 for recurrent respiratory papillomatosis and early programs in DNA encoded antibodies and proteins. What are the underlying business or industry changes driving this perspective?Read more
43
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$1.8
41.7% undervalued intrinsic discount
Fair Value
Profit Margin
0.93%
Future PE
129.8x
Price in 2029
US$2.22
RRP Treatment Breakthrough Will Transform DNA Medicines Platform Into A Durable Revenue Franchise
Catalysts About Inovio Pharmaceuticals Inovio Pharmaceuticals is a biotechnology company developing DNA medicines and delivery technologies to treat and prevent infectious diseases, cancers and rare disorders. What are the underlying business or industry changes driving this perspective?Read more
47
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$13
91.9% undervalued intrinsic discount
Fair Value
Profit Margin
16.24%
Future PE
32.83x
Price in 2028
US$15.98
DNA Medicines And Rare Disease Focus Will Transform Into A Future Commercial Revenue Story
Catalysts About Inovio Pharmaceuticals Inovio Pharmaceuticals is a biotechnology company focused on developing DNA based medicines for rare diseases, infectious diseases and cancer. What are the underlying business or industry changes driving this perspective?Read more
154
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$7.63
86.2% undervalued intrinsic discount
Fair Value
Profit Margin
0.16%
Future PE
24.82x
Price in 2028
US$0.09
Trending Discussion
Recently Updated Narratives
AN
Regulatory And Commercial Risks Around DNA Medicines Will Eventually Support A Healthier Outlook
Fair Value: US$1.8 41.7% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RRP Treatment Breakthrough Will Transform DNA Medicines Platform Into A Durable Revenue Franchise
Fair Value: US$13 91.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DNA Medicines And Rare Disease Focus Will Transform Into A Future Commercial Revenue Story
Fair Value: US$7.63 86.2% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Inovio Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.04
- -82,857.43%
- -130,000.00%
- 0%
About INO
- Founded
- 1983
- Employees
- 112
- CEO
- WebsiteView website
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company’s partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
